Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Rüdiger Hehlmann, Michael Lauseker et al.|Leukemia|2017Cited by 339
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IVSusanne Saußele, Michael Lauseker, Aloïs Gratwohl et al.|Blood|2009Cited by 220
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patientsAlexandros Spyridonidis, Mohamad Mohty, Gèrard Socié et al.|Bone Marrow Transplantation|2020Cited by 202
Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent YearsAli Bazarbachi, Mohamad Mohty, Christoph Schmid et al.|Clinical Cancer Research|2020Cited by 81